MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Avidity Biosciences Inc

Open

SectorHealthcare

45.37 3.02

Overview

Share price change

24h

Current

Min

43.68

Max

45.58

Key metrics

By Trading Economics

Income

-42M

-157M

Sales

2.3M

3.8M

Profit margin

-4,089.29

Employees

391

EBITDA

-40M

-171M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+59.07% upside

Market Stats

By TradingEconomics

Market Cap

1.8B

6.3B

Previous open

42.35

Previous close

45.37

News Sentiment

By Acuity

50%

50%

149 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Avidity Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sie 2025, 05:47 UTC

Acquisitions, Mergers, Takeovers

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

22 kwi 2025, 09:30 UTC

Top News

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Comparison

Price change

Avidity Biosciences Inc Forecast

Price Target

By TipRanks

59.07% upside

12 Months Forecast

Average 68.4 USD  59.07%

High 96 USD

Low 52 USD

Based on 15 Wall Street analysts offering 12 month price targets forAvidity Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

25.575 / 32.65Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

149 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat